John A. Lewicki - 11 Sep 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role: Chief Scientific Officer
Signature: /s/ Christine Fox, by power of attorney
Issuer symbol: MREO
Transactions as of: 11 Sep 2024
Net transactions value: $0
Form type: 4
Filing time: 13 Sep 2024, 16:49:18 UTC
Previous filing: 27 Jun 2024
Next filing: 16 Sep 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MREO	American Depositary Shares representing Ordinary Shares	Options Exercise	$0	+46,000	+94%	$0.000000	94,779	11 Sep 2024	Direct	F1, F2
holding	MREO	American Depositary Shares representing Ordinary Shares						14,196	11 Sep 2024	By The Lewicki Family Living Trust dated December 6, 2000	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MREO	Performance Based Restricted Stock Unit	Options Exercise	$0	-46,000	-100%	$0.000000	0	11 Sep 2024	American Depository Shares	46,000	$0.000000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2	Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period.